A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 34,600 shares of ABEO stock, worth $197,220. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,600
Previous 39,500 12.41%
Holding current value
$197,220
Previous $167,000 30.54%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.12 - $6.32 $14,506 - $22,252
-3,521 Reduced 83.24%
709 $4,000
Q2 2024

Aug 14, 2024

BUY
$3.17 - $8.05 $13,396 - $34,019
4,226 Added 105650.0%
4,230 $17,000
Q1 2024

May 15, 2024

SELL
$4.07 - $8.68 $370,842 - $790,886
-91,116 Reduced 100.0%
4 $0
Q4 2023

Feb 14, 2024

BUY
$3.71 - $5.14 $338,055 - $468,356
91,120 New
91,120 $456,000

Others Institutions Holding ABEO

About ABEONA THERAPEUTICS INC.


  • Ticker ABEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,950,380
  • Market Cap $33.9M
  • Description
  • Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...
More about ABEO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.